Tiziana Life rises 11% after submitting application to begin human trial of Alzheimer's intranasal therapy

Oct. 12, 2022 9:39 AM ETTiziana Life Sciences Ltd (TLSA)By: Dania Nadeem, SA News Editor

Alzheimer"s disease concept, Elderly woman holding brain symbol of missing jigsaw puzzle, World Alzheimer"s, World mental health, Memory loss, Dementia, Parkinson disease.


  • Tiziana Life Sciences (NASDAQ:TLSA) is trading 11.2% higher premarket after it plans to submit an application to begin Phase 1 trial of intranasal foralumab in Alzheimer's disease.
  • Tiziana plans on filing the Investigational New Drug Application for Alzheimer’s disease by Q3 2023 upon the completion of requested toxicology studies, and will start Phase 1 program by the end of 2023.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.